GE HealthCare receives CE Mark for new StarGuide GX system
Chicago: GE HealthCare has announced CE Mark for its new StarGuide GX system, a new digital 4D SPECT/CT.
This will help empower clinicians to expand research and help personalize care across a growing range of nuclear medicine applications and tracers – including the acquisition of alpha emitters, the company stated.
As complex diseases such as cancer, Alzheimer’s and cardiovascular disease become increasingly prevalent, the demand for precision diagnostics and targeted therapies is accelerating. StarGuide GX helps meet this need head-on, enabling clinicians to break free from energy-range limitations and image tracers with exceptional clarity.
“Our mission is to advance precision health by delivering technologies that meet the evolving needs of clinicians and patients,” shares Jean-Luc Procaccini, President and CEO, Molecular Imaging and Computed Tomography, GE HealthCare. “As nuclear medicine evolves to meet the demands of precision health, StarGuide GX is designed to help researchers and clinicians stay ahead, offering a whole new range of possibilities with one scanner. This innovation reflects our commitment to purposeful technology – supporting cases across care pathways and the practice of theranostics – to help both expand clinical capabilities and improve outcomes for patients worldwide.”
Powered by its dual-sided CZT detector technology, StarGuide GX is designed to deliver ultra-high sensitivity and high-resolution imaging – enabling fast, confident diagnostics. The system’s patented dual collimator detector design helps eliminate the need for traditional manual or automated external exchanges, streamlining workflows and helping users avoid physical strain. Moreover, StarGuide GX leverages NVIDIA RTX accelerated computing to optimize the reconstruction process and help reduce the time it takes to generate images.
Intentionally designed for versatility, StarGuide GX represents an all-in-one system virtually capable of imaging all energy levels for general-purpose SPECT imaging – as well as the acquisition of investigational alpha therapies such as Actinium-225 – with excellent image quality, optimizing it for exploring imaging of emerging therapies. The system’s ability to image closer to organs helps deliver excellent resolution and quantitation, both of which are important for treatment planning and monitoring. This enables clinicians to image tracers with exceptional clarity, with impressive workflow efficiency.
“StarGuide GX is an innovation sure to prove valuable now and in the future,” says Erez Levy, Executive Director, Molecular Imaging, GE HealthCare. “Its ability to image alpha emitters and deliver accurate quantitation in short scan times could create new opportunities for clinicians to personalize treatment with great confidence. This technology holds the promise of expanding nuclear medicine’s research capabilities and clinical practice – with the ultimate goal of improving outcomes for patients across a wide range of conditions.”
Operationally, StarGuide GX is designed to support clinical efficiency, enabling fast scans, precise dynamic imaging and helping reduce traditional collimator exchange workflows from minutes to seconds. It’s designed to reduce workload, helping departments manage growing patient volumes with limited resources. Additionally, the system features a lead-free laser-printed collimator that supports global sustainability goals and contributes to its impressive image quality.
Read also: GE HealthCare Revolution Vibe CT system gets USFDA clearance
